Apilimod displays antitumor activity in B-NHL in vivo. (A) Growth of Daudi Burkitt lymphoma xenograft tumors. Left, Graph of tumor size (mm3) over time (days). Right, Graph of body weight (g) over time (days). Dose is detailed in legend, ****P < .0001; compared with vehicle at last time point, 1-way analysis of variance (ANOVA), Dunnett's multiple comparisons test. Yellow triangles indicate the days which apilimod was dosed. N = 8 mice per treatment arm. Data are represented as mean ± standard error of the mean (SEM). (B) Apilimod displays growth inhibition in combination with rituximab in SU-DHL-6 DLBCL tumors in vivo. Left, Graph of tumor size (mm3) over time (days). Right, Graph of body weight (g) over time (days). *P < .05; **P < .01 compared with vehicle at last time point, 1-way ANOVA, Dunnett's multiple comparisons test. Coefficient of drug interaction (CDI), 0.8; CDI < 1 indicates synergism. Yellow and green triangles indicate the days which apilimod and rituximab were dosed. N = 6 mice per treatment arm. Data are represented as mean ± SEM. (C) Apilimod causes tumor growth inhibition in combination with anti-PD-L1 in A20 syngeneic model. Left, Graph of tumor size (mm3) over time (days). Right, Graph of body weight (g) over time (days). ***P < .001, ****P = .0001 compared with vehicle at last time point, 1-way ANOVA, Dunnett's multiple comparisons test. CDI, 0.62; CDI < 1 indicates synergism. Yellow and green triangles indicate the days which apilimod and anti-PD-L1 were dosed. N = 8 mice per treatment arm. Data are represented as mean ± SEM. BID, twice daily; BIW, twice weekly; i.p., intraperitoneal; p.o., oral gavage; Q4D, every 4 days; QD, once daily.
